ECSP23070062A - Nuevo agente de contraste para utilizar en imágenes por resonancia magnética - Google Patents

Nuevo agente de contraste para utilizar en imágenes por resonancia magnética

Info

Publication number
ECSP23070062A
ECSP23070062A ECSENADI202370062A ECDI202370062A ECSP23070062A EC SP23070062 A ECSP23070062 A EC SP23070062A EC SENADI202370062 A ECSENADI202370062 A EC SENADI202370062A EC DI202370062 A ECDI202370062 A EC DI202370062A EC SP23070062 A ECSP23070062 A EC SP23070062A
Authority
EC
Ecuador
Prior art keywords
magnetic resonance
contrast agent
resonance imaging
new contrast
compounds
Prior art date
Application number
ECSENADI202370062A
Other languages
English (en)
Inventor
Gregor Jost
Olaf Panknin
Jessica Lohrke
Simon Anthony Herbert
Hubertus Pietsch
Thomas Brumby
Markus Berger
Claudia Green
Thomas Frenzel
Sven Wittrock
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of ECSP23070062A publication Critical patent/ECSP23070062A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A61K49/108—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA the metal complex being Gd-DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se relaciona con una nueva clase de compuestos de fórmula general (I), con los complejos de quelato de Gd3+ de los mismos, con métodos para preparar dichos compuestos, y con el uso de dichos compuestos como agentes de contraste para IRM.
ECSENADI202370062A 2021-03-15 2023-09-14 Nuevo agente de contraste para utilizar en imágenes por resonancia magnética ECSP23070062A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP21162650.2A EP4059925A1 (en) 2021-03-15 2021-03-15 New contrast agent for use in magnetic resonance imaging

Publications (1)

Publication Number Publication Date
ECSP23070062A true ECSP23070062A (es) 2023-10-31

Family

ID=74874752

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202370062A ECSP23070062A (es) 2021-03-15 2023-09-14 Nuevo agente de contraste para utilizar en imágenes por resonancia magnética

Country Status (19)

Country Link
US (1) US20240182431A1 (es)
EP (2) EP4059925A1 (es)
JP (1) JP2024512459A (es)
KR (1) KR20230157412A (es)
CN (1) CN116981658A (es)
AR (1) AR126325A1 (es)
AU (1) AU2022236333A1 (es)
BR (1) BR112023017197A2 (es)
CA (1) CA3213386A1 (es)
CL (1) CL2023002723A1 (es)
CO (1) CO2023012137A2 (es)
CR (1) CR20230433A (es)
DO (1) DOP2023000185A (es)
EC (1) ECSP23070062A (es)
IL (1) IL305294A (es)
MX (1) MX2023010737A (es)
PE (1) PE20240821A1 (es)
TW (1) TW202302543A (es)
WO (1) WO2022194777A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4210069A1 (en) * 2022-01-11 2023-07-12 Bayer Aktiengesellschaft Synthetic contrast-enhanced ct images
WO2024046832A1 (de) 2022-08-30 2024-03-07 Bayer Aktiengesellschaft Erzeugen von synthetischen radiologischen aufnahmen
WO2024046831A1 (de) 2022-08-30 2024-03-07 Bayer Aktiengesellschaft Erzeugen von synthetischen radiologischen aufnahmen
WO2024046833A1 (de) 2022-08-30 2024-03-07 Bayer Aktiengesellschaft Erzeugen von synthetischen radiologischen aufnahmen
WO2024052156A1 (de) 2022-09-05 2024-03-14 Bayer Aktiengesellschaft Erzeugen von künstlichen kontrastverstärkten radiologischen aufnahmen
EP4336204A1 (de) 2022-09-07 2024-03-13 Bayer AG Beschleunigen von mrt-untersuchungen der leber
EP4335462A1 (en) * 2022-09-09 2024-03-13 Bayer AG Contrast agents for use in diagnostic computed tomography imaging
WO2024083466A1 (de) 2022-10-17 2024-04-25 Bayer Aktiengesellschaft Automatisches analysieren von radiologischen aufnahmen
EP4369353A1 (de) 2022-11-12 2024-05-15 Bayer Aktiengesellschaft Erzeugung von künstlichen kontrastmittelverstärkten radiologischen aufnahmen
EP4369285A1 (de) 2022-11-12 2024-05-15 Bayer AG Erzeugung von künstlichen kontrastmittelverstärkten radiologischen aufnahmen
EP4375919A1 (de) 2022-11-25 2024-05-29 Bayer AG Erzeugen von kontrastverstärkten synthetischen radiologischen aufnahmen

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5560903A (en) 1981-07-24 1996-10-01 Schering Aktiengesellschaft Method of enhancing paramagnetism in chelates for MRI
DE3922005A1 (de) 1989-06-30 1991-01-10 Schering Ag Derivatisierte dtpa-komplexe, diese verbindungen enthaltende pharmazeutische mittel, ihre verwendung und verfahren zu deren herstellung
GB9407435D0 (en) 1994-04-14 1994-06-08 Nycomed Salutar Inc Compounds
IT1269839B (it) 1994-05-26 1997-04-15 Bracco Spa Coniugati di acidi biliari, loro derivati con complessi metallici e relativi usi
US5672335A (en) 1994-11-30 1997-09-30 Schering Aktiengesellschaft Use of metal complexes as liver and gallbladder X-ray diagnostic agents
IT1283218B1 (it) 1996-03-08 1998-04-16 Bracco Spa Polichelanti, loro complessi con ioni metallici, loro preparazione e loro usi
IT1293778B1 (it) 1997-07-25 1999-03-10 Bracco Spa 1,4,7,10-tetraazabiciclo(8.2.2.)tetradecan-2 one, sua preparazione e suo uso per la preparazione di tetraazamacrocicli
EP1278553A2 (en) 2000-05-04 2003-01-29 Research Corporation Technologies, Inc Magnetic resonance imaging agents for the delivery of therapeutic agents
DE10135356C1 (de) * 2001-07-20 2003-04-17 Schering Ag Makrocyclische Metallkomplexe und deren Verwendung zur Herstellung von Konjugaten mit Biomolekülen
DE10231799B4 (de) 2002-07-10 2006-10-05 Schering Ag Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel im MR-Imaging zur Darstellung von Intravasalen Thromben
DE102005033902B3 (de) 2005-07-15 2007-04-05 Schering Ag Perfluoralkylhaltige Komplexe, Verfahren zu deren Herstellung, sowie deren Verwendung und diese enthaltende pharmazeutische Mittel
US9693828B2 (en) 2011-12-05 2017-07-04 Bracco Imaging S.P.A. Composition comprising acetic anhydride and a gadolinium complex, and method for the use in hyperpolarisation in MRI analysis
JP2022529379A (ja) * 2019-04-26 2022-06-21 ファイブ イレブン ファーマ インコーポレイテッド 診断および放射性核種治療剤としての前立腺特異的膜抗原（ｐｓｍａ）阻害剤

Also Published As

Publication number Publication date
IL305294A (en) 2023-10-01
CR20230433A (es) 2023-10-23
TW202302543A (zh) 2023-01-16
EP4059925A1 (en) 2022-09-21
CO2023012137A2 (es) 2023-09-29
EP4308551A1 (en) 2024-01-24
JP2024512459A (ja) 2024-03-19
CN116981658A (zh) 2023-10-31
CL2023002723A1 (es) 2024-01-26
MX2023010737A (es) 2023-09-20
DOP2023000185A (es) 2023-10-15
CA3213386A1 (en) 2022-09-22
BR112023017197A2 (pt) 2023-09-26
AR126325A1 (es) 2023-10-04
WO2022194777A1 (en) 2022-09-22
PE20240821A1 (es) 2024-04-18
US20240182431A1 (en) 2024-06-06
AU2022236333A1 (en) 2023-08-31
KR20230157412A (ko) 2023-11-16

Similar Documents

Publication Publication Date Title
CO2023012137A2 (es) Nuevo agente de contraste para utilizar en imágenes por resonancia magnética
CL2017003083A1 (es) Nuevos compuestos de quelato de gadolinio para usar en imágenes de resonancia magnética
CO6501196A2 (es) Compuestos antiproliferativos, cojugados de los mismos, procedimientos para éstos y uso de los mismos
PE20160678A1 (es) Inhibidores marcados de antigeno prostatico especifico de membrana (psma), su uso como agentes formadores de imagenes y agentes farmaceuticos para el tratamiento de cancer de prostata
UY37500A (es) Nuevos compuestos de quelato de gadolinio con alta relaxividad para usar en la obtencion de imagenes por resonancia magnetica
CO7141456A2 (es) Derivados de aril-sultamo como moduladores de rorc
MX2013009688A (es) Composiciones para teñido oxidativo que comprende un 1-hexil/heptil-4,5-diaminopirazol y un m-aminofenoly derivados de estos.
AR095426A1 (es) Inhibidores tripeptídicos de la epoxicetona proteasa
CR20140089A (es) Nuevos derivados bicíclicos de dihidroquinolina-2-ona
MX2013009690A (es) Composiciones para teñido oxidativo que comprenden un 1-hextil/heptil-4,5-diaminopirazol y una benceno-1,-3-diamina y derivados de estos.
MX2018007043A (es) Agentes de contraste dimericos.
CR10654A (es) Agentes que comprenden compuestos marcados con 18f y metodos relacionados
DOP2017000202A (es) Desacetoxitubulisina h y análogos de esta
BR112018076389A2 (pt) composto, método para preparação de um composto, e, composição farmacêutica.
MX2016003725A (es) Compuestos y su uso para la preparacion de agentes de formacion de imagen tau y formulaciones para la formacion de imagen tau.
PE20211471A1 (es) Formulacion de medios de contraste y proceso para prepararlos
BR112022003242A2 (pt) Composto, composição, e, métodos de formação de imagens, de síntese enantiosseletiva e de produção
CO2021009388A2 (es) Nanopartícula, agente de contraste para formación de imágenes por resonancia magnética que comprende la misma y un compuesto de ligando zwitteriónico
AR093168A1 (es) COMPUESTOS DE OXAZOLIDINONA COMO INHIBIDORES DEL CANAL KCa3.1
AR094057A1 (es) Compuestos amina y uso de los mismos como neutralizantes de voc bajo o cero
AR095353A1 (es) Compuesto
UY35544A (es) Complejos de bis azainositol hafnio para adquisición de imágenes por rayos x
AR120033A1 (es) Antagonista radiomarcado de grpr para uso como agente teragnóstico
DOP2009000036A (es) Agentes que comprenden compuestos marcados con 18f y metodos relacionados
PA8757701A1 (es) Nuevos derivados de benzotiazinona, su preparacion y uso como actibacterianos